Egalet Corporation (NASDAQ:EGLT) Ratings Summary as of May 16, 2018

May 16, 2018 - By Jack Shaw

Egalet Corporation (NASDAQ:EGLT) Corporate Logo
During 2017 Q4 the big money sentiment decreased to 0.47. That’s change of 0.11, from 2017Q3’s 0.58. 13 investors sold all, 17 reduced holdings as Egalet Corporation ratio worsened. 8 rose positions while 6 funds took positions. Funds hold 13.62 million shares thus 32.80% less from 2017Q3’s 20.27 million shares.
Franklin Resources Inc holds 2.73 million shs. Macquarie Grp holds 31,300 shs. Raymond James Financial Ser holds 0% or 16,884 shs. Bridgeway Mgmt Inc holds 0% of its capital in Egalet Corporation (NASDAQ:EGLT) for 74,400 shs. California Employees Retirement invested 0% in Egalet Corporation (NASDAQ:EGLT). Ontario – Canada-based Royal Bancshares Of Canada has invested 0% in Egalet Corporation (NASDAQ:EGLT). Atlantic Tru Gp Lc invested 0% of its capital in Egalet Corporation (NASDAQ:EGLT). Nj State Employees Deferred Compensation Plan holds 230,000 shs. Two Sigma Secs Lc reported 57,835 shs. Highland Cap Ltd Partnership reported 119,520 shs stake. Janney Montgomery Scott Ltd Company accumulated 22,159 shs. Barclays Public Ltd owns 65 shs for 0% of their capital. Fmr Llc holds 767,013 shs. Bnp Paribas Arbitrage has invested 0% in Egalet Corporation (NASDAQ:EGLT). Wells Fargo And Mn invested 0% in Egalet Corporation (NASDAQ:EGLT).

Egalet Corporation (NASDAQ:EGLT) Ratings Coverage

Total analysts of 2 have positions in Egalet (NASDAQ:EGLT) as follows: 0 rated it a “Buy”, 0 with “Sell” and 2 with “Hold”. The positive are 0. Since January 3, 2018 according to StockzIntelligence Inc Egalet has 3 analyst reports. On Monday, March 12 the stock of Egalet Corporation (NASDAQ:EGLT) earned “Buy” rating by Cantor Fitzgerald. The company rating was downgraded by Stifel Nicolaus on Wednesday, January 3. On Tuesday, May 8 the rating was downgraded by Cantor Fitzgerald to “Hold”. Listed here are Egalet Corporation (NASDAQ:EGLT) PTs and latest ratings.

08/05/2018 Broker: Cantor Fitzgerald Rating: Hold New Target: $1.5000 Downgrade
12/03/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $3.5 Maintain
03/01/2018 Broker: Stifel Nicolaus Old Rating: Buy New Rating: Hold Downgrade

Ticker’s shares touched $0.5 during the last trading session after 11.50% change.Egalet Corporation has 2.09 million shares volume, 142.29% up from normal. EGLT is downtrending and has moved 87.31% since May 16, 2017. The stock underperformed the S&P500 by 98.86%.

Egalet Corporation, a specialty pharmaceutical company, develops, makes, and commercializes treatments for patients with pain and other conditions.The firm is valued at $26.43 million. It has licensed three approved pain products, such as SPRIX Nasal Spray, a non-steroidal anti-inflammatory drug indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level; OXAYDO, an immediate-release oxycodone product designed to discourage abuse via snorting for the management of acute and chronic moderate to severe pain where an opioid is appropriate; and ARYMO ER, an extended-release morphine product formulated with abuse-deterrent (AD) properties for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.Currently it has negative earnings. The firm is also developing Egalet-002, a Guardian Technology AD, ER, oral oxycodone formulation, which is in Phase III clinical trials for the same indication as ARYMO ER.

There’s a significant Egalet Corporation (NASDAQ:EGLT) news released by Seekingalpha.com. It’s an article titled: “Egalet’s (EGLT) CEO Bob Radie on Q1 2018 Results – Earnings Call Transcript” on May 09, 2018.

Egalet Corporation (NASDAQ:EGLT) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: